- Home
- Results news
- Sanofi Consumer Healthcare India
- Q2 FY27 results
Sanofi Consumer Healthcare India Q2 FY27 results: net profit up 21.8% to ₹76.60 crore, revenue up 12.5%
Sanofi Consumer Healthcare India Limited reported standalone revenue of ₹263.10 crore in Q2 FY27, up 12.5% from Q2 FY26 and 11.6% from Q1 FY27. Net profit rose to ₹76.60 crore from ₹62.90 crore a year earlier, while EBITDA margin expanded to 38.7%.
Key points
- Q2 FY27 revenue was ₹263.10 crore, up 12.5% from ₹233.90 crore in Q2 FY26.
- EBITDA was ₹101.70 crore in Q2 FY27, up 19.6% from ₹85 crore in Q2 FY26.
- Net profit for the quarter was ₹76.60 crore, compared with ₹62.90 crore in Q2 FY26 and ₹68.80 crore in Q1 FY27.
- Basic EPS was ₹33.26, compared with ₹27.31 in Q2 FY26 and ₹29.87 in Q1 FY27.
- For H1 FY27, revenue was ₹728.0 crore and net profit was ₹213.2 crore.
How did Sanofi Consumer Healthcare India perform in Q2 FY27?
Sanofi Consumer Healthcare India reported standalone revenue of ₹263.10 crore for Q2 FY27, compared with ₹233.90 crore in Q2 FY26 and ₹235.70 crore in Q1 FY27. Revenue rose 12.5% year on year and 11.6% from the previous quarter. Total income was ₹267.50 crore in the quarter, while EBITDA reached ₹101.70 crore, up 19.6% from ₹85 crore in the year-ago quarter and 13.9% from ₹89.30 crore in Q1 FY27.
EBITDA margin was 38.7% in Q2 FY27, compared with 36.3% in Q2 FY26 and 37.9% in Q1 FY27. Profit before tax was ₹102.70 crore, up 22.1% from ₹84.10 crore a year earlier and 11.8% from ₹91.90 crore in the previous quarter. Net profit was ₹76.60 crore, up 21.8% from ₹62.90 crore in Q2 FY26 and 11.3% from ₹68.80 crore in Q1 FY27. Basic EPS was ₹33.26, compared with ₹27.31 and ₹29.87, respectively. The figures are on a standalone basis.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 263.10 | 235.70 | 233.90 | +12.5% | +11.6% |
| Other income | 4.40 | 6.30 | 3 | +46.7% | −30.2% |
| Total expenses | 164.80 | 150.10 | 152.80 | +7.9% | +9.8% |
| EBITDA | 101.70 | 89.30 | 85 | +19.6% | +13.9% |
| EBITDA margin | 38.7% | 37.9% | 36.3% | +2.4 pp | +0.8 pp |
| Profit before tax | 102.70 | 91.90 | 84.10 | +22.1% | +11.8% |
| Tax | 26.10 | 23.10 | 21.20 | +23.1% | +13.0% |
| Net profit | 76.60 | 68.80 | 62.90 | +21.8% | +11.3% |
| EPS (₹) | 33.26 | 29.87 | 27.31 | +21.8% | +11.3% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Sanofi Consumer Healthcare India's costs and profit?
Total expenses increased to ₹164.80 crore in Q2 FY27 from ₹152.80 crore in Q2 FY26, a rise of 7.9%. Cost of materials consumed rose ₹4.20 crore, or 11.5%, to ₹40.70 crore, while other expenses increased ₹10.90 crore, or 19.7%, to ₹66.30 crore. Employee cost fell ₹1 crore, or 3.2%, to ₹30.70 crore, finance costs declined ₹0.30 crore, or 50.0%, and depreciation fell ₹0.20 crore, or 6.1%.
Other income increased ₹1.40 crore, or 46.7%, to ₹4.40 crore from ₹3 crore in the year-ago quarter. There was no exceptional item in Q2 FY27, compared with an exceptional item of ₹66 crore in H1 FY26. Tax expense rose ₹4.90 crore, or 23.1%, to ₹26.10 crore from ₹21.20 crore. The filing did not state the reasons for the changes in costs, other income or tax.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 40.70 | 36.50 | +4.20 | +11.5% |
| Employee cost | 30.70 | 31.70 | −1 | −3.2% |
| Finance costs | 0.30 | 0.60 | −0.30 | −50.0% |
| Depreciation | 3.10 | 3.30 | −0.20 | −6.1% |
| Other expenses | 66.30 | 55.40 | +10.90 | +19.7% |
| Total expenses | 164.80 | 152.80 | +12 | +7.9% |
| Other income | 4.40 | 3 | +1.40 | +46.7% |
| Tax | 26.10 | 21.20 | +4.90 | +23.1% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In the first half of FY27, Sanofi Consumer Healthcare India reported standalone revenue of ₹728.0 crore, up 16.0% from ₹627.4 crore in H1 FY26. Total income rose 16.1% to ₹744.3 crore from ₹641.2 crore, while profit before tax increased 24.2% to ₹285.3 crore from ₹229.8 crore.
Net profit for H1 FY27 was ₹213.2 crore, up 22.8% from ₹173.6 crore in H1 FY26. Basic EPS was ₹92.57, compared with ₹75.38 in the year-ago first half. H1 FY27 included no exceptional item, while H1 FY26 included an exceptional item of ₹66 crore.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 728 | 627.40 | +16.0% |
| Profit before tax | 285.30 | 229.80 | +24.2% |
| Net profit | 213.20 | 173.60 | +22.8% |
| EPS (₹) | 92.57 | 75.38 | +22.8% |
Source: Company's results filing (XBRL).
How has Sanofi Consumer Healthcare India done over the last 8 quarters?
Revenue and profit have risen year on year in each of the last six quarters. Revenue increased from ₹170.70 crore in Q3 FY25 to a high of ₹263.10 crore in Q2 FY27, while net profit rose from ₹44.30 crore to a high of ₹76.60 crore over the same period. Q2 FY27 was the latest quarter in the series and showed continued growth in both measures.
EBITDA margin was 36.4% in Q3 FY25 and reached 38.7% in Q2 FY27, with 38.7% also recorded in Q4 FY26. The margin fell to 31.8% in Q1 FY26 before recovering in the following quarters. After reaching a low of ₹229.20 crore in Q4 FY26, revenue rose to ₹235.70 crore in Q1 FY27 and ₹263.10 crore in Q2 FY27; profit after tax also increased from ₹67.80 crore to ₹68.80 crore and then ₹76.60 crore.
How did Sanofi Consumer Healthcare India shares react?
Sanofi Consumer Healthcare India’s stock was up 6.0% five minutes after the filing appeared, then moved 0.1% lower after 15 minutes and was up 0.9% after 30 minutes. On the reaction day, the stock closed 3.9% above its previous close, compared with a 0.4% median move for the Pharmaceuticals industry. By the next day’s close, it was up 2.1% from the pre-results close, while the industry median was down 0.7%.
The stock’s reaction-day move exceeded the industry median by 3.6 percentage points, and its cumulative move by the next day’s close exceeded the industry median by 2.7 percentage points. Earlier results-day moves were mixed: the stock was up 15.9% on 25 February 2026, up 12.8% on 4 August 2025 and down 2.1% on 20 February 2025. The filing was announced after market on 28 October 2026.
| After the filing | Stock | Pharmaceuticals median |
|---|---|---|
| 5 minutes | +6.0% | |
| 15 minutes | −0.1% | |
| 30 minutes | +0.9% | |
| Reaction day | +3.9% | +0.4% |
| Next day | +2.1% | −0.7% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 28 July 2026 | +0.4% |
| 28 April 2026 | +3.2% |
| 25 February 2026 | +15.9% |
| 12 November 2025 | +7.6% |
| 4 August 2025 | +12.8% |
| 2 May 2025 | +0.2% |
| 20 February 2025 | −2.1% |
| 12 November 2024 | −0.5% |
Source: MarketPing price-reaction measurement.
How did other Pharmaceuticals companies do?
Among 60 Pharmaceuticals companies that filed for the quarter, the median revenue growth was 19.8%. Twenty peers grew more slowly than Sanofi Consumer Healthcare India, while 40 grew faster. Of the 54 peers for which profit was compared, 38 reported higher profit. The peer comparison is as of 4 November 2026.
| Sanofi Consumer Healthcare India revenue growth (YoY) | +12.5% |
|---|---|
| Median of 60 other Pharmaceuticals companies | +19.8% |
| Companies with slower revenue growth than Sanofi Consumer Healthcare India | 20 of 60 |
| Companies with faster revenue growth than Sanofi Consumer Healthcare India | 40 of 60 |
| Companies whose net profit rose | 38 of 54 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Sanofi Consumer Healthcare India's revenue in Q2 FY27?
Revenue from operations was ₹263.10 crore, up 12.5% from ₹233.90 crore in Q2 FY26 (standalone).
Did Sanofi Consumer Healthcare India make a profit in Q2 FY27?
Yes. Net profit was ₹76.60 crore, against a net profit of ₹62.90 crore in Q2 FY26.
What was Sanofi Consumer Healthcare India's EPS in Q2 FY27?
Basic earnings per share were ₹33.26, against ₹27.31 in Q2 FY26.
How did Sanofi Consumer Healthcare India shares react to the Q2 FY27 results?
On the reaction day the stock moved +3.9% from the previous close; the median Pharmaceuticals stock moved +0.4%.
When did Sanofi Consumer Healthcare India announce its Q2 FY27 results?
On 28 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2026. (BSE, 22 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, 28Th October 2026 (BSE, 28 October 2026) · PDF
- Results - Financial Results For September 30, 2026 (BSE, 28 October 2026) · PDF
- Announcement under Regulation 30 (LODR)-Press Release / Media Release (BSE, 28 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.